8th JUNE 2020, HONG KONG – Pangenia Life Sciences announced that it will be part of a new international collaborative effort of providing new assay service in Hong Kong. We have signed a collaboration agreement with Genomic Vision (GV).
GV has developed and owns a proprietary molecular combing technology allowing to stretch long DNA molecule and to label regions of interest using fluorescence in the genome using the Genomic Morse Code (GMC) technology and their subsequent detection allowing the visualization of large regions of the genome for the discovery of DNA structural variations, replications and dynamic genomic events (the “GV Technology”).
We are pleased to announce we have reached a partnership agreement with Genomic Vision to provide the molecular combing service in Hong Kong. This new technology will bring new approaches for genomic analysis to our customers and widen our life science profile.
About Genomic Vision
GENOMIC VISION is a company specialized in the development of diagnostic solutions for the early detection of cancers and serious genetic diseases and tools for life sciences research. Through the DNA Molecular Combing, a strong proprietary technology allowing to identify genetic abnormalities, GENOMIC VISION stimulates the R&D productivity of the pharmaceutical companies, the leaders of the diagnostic industry and the research labs.
The Company develops a robust portfolio of diagnostic tests (breast, ovarian and colorectal cancers, myopathies) and analysis tools (DNA replication, biomarkers discovery, gene editing quality control). Based near Paris, in Bagneux, the Company has approximately 60 employees. GENOMIC VISION is a public listed company listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV – ISIN: FR0011799907).
About Pangenia Life Sciences
Pangenia Life Sciences is a wholly owned subsidiary of Pangenia Inc, a leading molecular diagnostics (MDx) group in Hong Kong founded by Professor Joseph Wing-On Tam. Pangenia Life Sciences provides genetic screening and advisory services to healthcare professionals and patients. Our tests, which include the latest NGS (Next Generation Sequencing) technology, help healthcare specialists and patients benefit from recent advances in preventive, predictive and personalized medicine.
Our wide and growing range of molecular diagnostic tests include hereditary risk assessments and genetic testing for personalized medicine. We actively works with commercial, institutional and governmental organizations across the world, remaining at the forefront of advanced molecular diagnostics, and educating the general public about the benefits of molecular diagnostics.